Understanding Heart Risks After COVID-19 Vaccination: Latest CDC and FDA Guidance

As of April 2026, ongoing monitoring continues to assess the relationship between COVID-19 vaccines and cardiovascular health, particularly regarding rare instances of myocarditis and pericarditis. Current guidance from the Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) emphasizes the importance of staying up to date with vaccination even as providing clear recommendations for managing potential cardiac side effects.

What Are Myocarditis and Pericarditis?

Myocarditis is inflammation of the heart muscle, and pericarditis is inflammation of the lining outside the heart. When both conditions occur together, it is referred to as myopericarditis. These conditions can arise in response to various triggers, including infections or, in rare cases, certain medications or vaccines. Symptoms may include chest pain, shortness of breath, or an abnormal heartbeat.

CDC Guidance on Myocarditis After COVID-19 Vaccination

The CDC has identified a rare but real association between mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) and cases of myocarditis and pericarditis, particularly in adolescent and young adult males within seven days after receiving the second dose. However, cases have likewise been reported in females, other age groups, and after other doses. Most patients experience resolution of symptoms by hospital discharge.

The CDC recommends that individuals who develop myocarditis or pericarditis after a COVID-19 vaccine dose should not receive additional doses until consulting the latest guidance in the Interim Clinical Considerations for Use of COVID-19 Vaccines. All suspected cases should be reported to the Vaccine Adverse Event Reporting System (VAERS).

FDA Labeling Updates for COVID-19 Vaccines

In June 2025, the FDA finalized updated warnings for the Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) COVID-19 vaccines to include more specific information about the risk of myocarditis and pericarditis. Based on analyses of commercial health insurance claims data, the estimated incidence during the first week after vaccination is approximately 8 cases per million doses in individuals aged 6 months through 64 years, and approximately 27 cases per million doses in males aged 12 through 24 years.

The FDA notes that follow-up data from longitudinal observational studies indicate that most hospitalized patients with vaccine-associated myocarditis had received a two-dose primary series of an mRNA vaccine prior to diagnosis, and many experienced symptom resolution over time.

Considerations for Individuals with Pre-Existing Heart Conditions

For older adults with coronary artery disease or heart failure, the long-term cardiac effects of COVID-19 vaccination remain an area of ongoing study. While these individuals face heightened risks from COVID-19 infection itself, current evidence does not establish a clear link between vaccination and worsened cardiovascular outcomes in this population. Decisions about vaccination should be made in consultation with a healthcare provider, weighing the protective benefits against individual health circumstances.

Reporting and Monitoring

Both the CDC and FDA stress the importance of vigilant monitoring and reporting. Healthcare providers and patients are encouraged to report any adverse events following vaccination to VAERS. Ongoing studies continue to evaluate the long-term cardiovascular effects of vaccination, particularly in higher-risk groups.

Key Takeaways

• Myocarditis and pericarditis after COVID-19 vaccination are rare but have been causally associated with mRNA vaccines, primarily in young males after the second dose.
• The CDC advises against additional doses following a diagnosed case until consulting updated clinical guidance.
• The FDA has strengthened vaccine labeling to reflect age- and sex-specific risk estimates based on recent data.
• Most patients with vaccine-associated myocarditis experience symptom resolution with appropriate care.
• Individuals with pre-existing heart conditions should discuss vaccination risks and benefits with their doctor.
• Reporting to VAERS remains critical for ongoing vaccine safety monitoring.

Frequently Asked Questions

Can I still get a COVID-19 vaccine if I had myocarditis after a previous dose?

According to CDC guidance, individuals who develop myocarditis or pericarditis after a COVID-19 vaccine dose should consult their healthcare provider and refer to the latest Interim Clinical Considerations before receiving additional doses. Vaccination decisions are made on a case-by-case basis.

Are the heart risks associated with COVID-19 vaccines higher than those from the virus itself?

While the vaccines carry a little risk of myocarditis, particularly in specific demographics, COVID-19 infection is associated with a significantly higher risk of cardiac complications, including myocarditis, heart failure, and arrhythmias. The protective benefits of vaccination against severe disease generally outweigh the rare risks of vaccine-associated heart inflammation for most populations.

How long does it take to recover from vaccine-associated myocarditis?

Most patients with myocarditis following mRNA COVID-19 vaccination experience resolution of symptoms by the time of hospital discharge, according to CDC data. Recovery timelines vary, and ongoing follow-up with a cardiologist is often recommended to ensure complete healing.